Scribe Therapeutics, Inc.
Scribe Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company developing precision-engineered CRISPR genetic medicines. Its wholly owned pipeline focuses on cardiometabolic diseases, including atherosclerotic cardiovascular disease, while collaborations with Eli Lilly and Sanofi apply its ELXR and XE technologies to additional therapeutic areas.
Business
Share of revenueGenetic medicine programs targeting cardiometabolic diseases such as ASCVD.
ELXR and XE platforms designed to support precision gene-editing applications.
Partner-funded development programs with Eli Lilly, Sanofi, and other potential collaborators.
Customers
Scribe's current commercial counterparties are biopharmaceutical collaborators, including Eli Lilly and Sanofi, which license or fund applications of its gene-editing technologies in selected therapeutic areas. These partners provide research funding, upfront payments, milestone opportunities, and potential royalties while contributing development and commercialization capabilities. Future end-market customers would include healthcare providers, payors, and patients if Scribe's product candidates receive regulatory approval.
License Scribe's CRISPR platforms and fund therapeutic development in selected disease areas.
Would administer or prescribe approved genetic medicines for cardiometabolic and other diseases.
Would reimburse approved therapies and influence patient access through coverage decisions.
Would receive durable, potentially single-administration treatments for serious diseases.
Strategy
Scribe's strategy is to advance its wholly owned cardiometabolic pipeline while using its CRISPR platforms in collaborations that broaden therapeutic reach and provide non-dilutive funding. Near-term development priorities include progressing STX-1150, advancing additional preclinical and clinical programs, and building manufacturing, clinical, intellectual-property, and public-company capabilities. Collaborations with Eli Lilly and Sanofi are intended to validate platform versatility and share development and commercialization requirements.
Clinical progress is required to convert the technology platform into proprietary medicines.
Collaborations extend applications of ELXR and XE while sharing development and commercialization resources.
Manufacturing, clinical, regulatory, and commercial capabilities are necessary for eventual product approval and launch.
Geography
Scribe Therapeutics is headquartered and organized in the United States, where its research, corporate, clinical-development, and public-company activities are managed. The company does not disclose country-level revenue or a regional revenue mix in the provided materials. Its collaborations and future clinical programs may require international regulatory, trial, manufacturing, and commercialization activities.
Risks
Scribe remains dependent on successful research, preclinical and clinical development, regulatory approval, and eventual market access because it has no approved products or product sales. Its collaboration-based revenue model exposes it to partner decisions on funding, trial execution, and commercialization, while the capital-intensive pipeline creates ongoing financing and dilution risk. Competition from established gene-editing and pharmaceutical companies, intellectual-property challenges, manufacturing constraints, and difficulty recruiting specialized personnel could delay or prevent commercialization.
- Funding and dilution riskImpact: CriticalLikelihood: High
The company has significant operating losses and negative operating cash flow while development requires substantial capital.
Exposure - Clinical-stage development failureImpact: CriticalLikelihood: Medium
Safety, efficacy, enrollment, manufacturing, or regulatory problems could prevent approval of product candidates.
Exposure: STX-1150 and other preclinical or clinical programs
- Collaboration dependenceImpact: HighLikelihood: Medium
Partners may delay, reduce, or terminate programs and control resources dedicated to development and commercialization.
Exposure - Competitive pressureImpact: HighLikelihood: Medium
Large pharmaceutical and biotechnology companies may have greater development, regulatory, manufacturing, and marketing resources.
Exposure: Gene editing and cardiometabolic therapeutic markets
- Market access and reimbursementImpact: HighLikelihood: Medium
Approved therapies may face restrictive coverage, inadequate reimbursement, or limited provider and patient adoption.
Exposure: Future commercialized genetic medicines
- Key personnel dependenceImpact: MediumLikelihood: Medium
Loss of technical, scientific, or management personnel could delay programs and weaken execution.
Exposure
Accounting
Judgemental itemsUpfront, milestone, contingent, FTE, and reimbursement payments may be recognized at different times based on performance obligations and reversal constraints.
Impact: Revenue can fluctuate substantially between reporting periods without corresponding product sales.
Milestone consideration is included in transaction price only when achievement is probable and a significant reversal is unlikely.
Impact: Clinical and regulatory progress can change the timing of reported collaboration revenue.
The Lilly convertible note is remeasured using assumptions about expected conversion.
Impact: Changes in valuation create non-operating earnings volatility.
Internal and external R&D costs are expensed as incurred, while advance payments are deferred until goods or services are received.
Impact: Timing of vendor delivery and clinical services affects reported operating expenses.
Net operating losses and other tax attributes are offset by a full valuation allowance because realization is uncertain.
Impact: Tax benefits are generally not recognized until future taxable income becomes more probable.
Similar listed companies
Publicly listed companies with a comparable business focus.
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Grace Therapeutics, Inc.
GRCE · Pharmaceutical Preparations
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Lexeo Therapeutics, Inc.
LXEO · Biological Products, (No Diagnostic Substances)
Lexeo Therapeutics is a U.S.-based clinical-stage biotechnology company developing gene therapy candidates for serious cardiovascular and neuromuscular diseases.
Sarepta Therapeutics, Inc.
SRPT · Pharmaceutical Preparations
Sarepta Therapeutics is a U.S.-based commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy,…
Intellia Therapeutics, Inc.
NTLA · In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies.
Last updated: 24/09/2026